Mirabegron Tablet in pharma franchise in Gujarat

Mirabegron Tablet in PCD pharma franchise in Sikkim

Mirabegron Tablet in top pharma company in Srinagar

Mirabegron Tablet in pcd pharma supplier in Kanpur

Mirabegron Tablet in phama franchise company in India
Mirabegron Tablet in phama distributor in Kota

Miratyle S 50-5 Tablet

Composition : Mirabegron 50mg + Solifenacine Succinate I.P. 5mg

Dosage Form : Tablet

Packaging Type : Alu-Alu

Packaging : 10x10

Price : ₹1/-

Please Contact For Best Price

Miratyle S 50/5 Tablet is a combination of Mirabegron (50mg) and Solifenacin Succinate I.P. (5mg), formulated to provide comprehensive management of overactive bladder (OAB) symptoms. Mirabegron, a beta-3 adrenergic agonist, enhances bladder storage capacity by relaxing the detrusor muscle during the storage phase. Solifenacin Succinate, a muscarinic receptor antagonist, reduces involuntary bladder contractions and urgency. Together, these components synergistically alleviate urinary frequency, urgency, and urge incontinence, offering a dual mechanism of action for better symptom control and improved patient compliance.

This dual-action therapy is ideal for patients who experience insufficient symptom relief with monotherapy or who need a broader therapeutic approach to manage OAB. The tablet is designed for once-daily administration, providing convenience and sustained relief throughout the day.

Read More

About the Product

Miratyle S 50/5 Tablet is a combination of Mirabegron (50mg) and Solifenacin Succinate I.P. (5mg), formulated to provide comprehensive management of overactive bladder (OAB) symptoms. Mirabegron, a beta-3 adrenergic agonist, enhances bladder storage capacity by relaxing the detrusor muscle during the storage phase. Solifenacin Succinate, a muscarinic receptor antagonist, reduces involuntary bladder contractions and urgency. Together, these components synergistically alleviate urinary frequency, urgency, and urge incontinence, offering a dual mechanism of action for better symptom control and improved patient compliance.

This dual-action therapy is ideal for patients who experience insufficient symptom relief with monotherapy or who need a broader therapeutic approach to manage OAB. The tablet is designed for once-daily administration, providing convenience and sustained relief throughout the day.

Common side effects may include dry mouth, constipation, increased blood pressure, headache, and dizziness.

For the treatment of overactive bladder (OAB) symptoms, including urinary urgency, increased frequency, and urge incontinence.

Use only under medical supervision. Avoid in patients with severe liver or kidney impairment or uncontrolled hypertension.

Store in a cool, dry place below 30°C, away from light and moisture.

Get in Touch